132nd MAINE LEGISLATURE
		LD 107		LR 62(02)
	An Act to Require Health Insurance Coverage for Biomarker Testing
	Fiscal Note for Bill as Amended by Committee Amendment " "
	Committee: Health Coverage, Insurance and Financial Services
	Fiscal Note Required: Yes
Fiscal Note
			FY 2025-26	FY 2026-27	Projections  FY 2027-28	Projections  FY 2028-29
Net Cost (Savings)
	General Fund		$0	$1,163,349	$2,287,608	$2,289,253
	Highway Fund		$0	$0	$6,113	$6,113
Appropriations/Allocations
	General Fund		$0	$1,163,349	$2,287,608	$2,289,253
	Highway Fund		$0	$0	$6,113	$6,113
	Federal Expenditures Fund		$0	$2,158,291	$4,258,602	$4,260,285
	Federal Block Grant Fund		$0	$12,773	$25,546	$25,546
Revenue
	Federal Expenditures Fund		$0	$2,158,291	$4,258,602	$4,260,286
	Federal Block Grant Fund		$0	$12,773	$25,546	$25,546
Fiscal Detail and Notes
	The bill includes General Fund appropriations to the Department of Health and Human Services of $993,349 in fiscal year 2026-27 to provide coverage for biomarker testing in the MaineCare program beginning January 1, 2027 and to establish one Health Services Consultant position in the Office of MaineCare Services to conduct prior authorization work. Federal Expenditures Fund and Federal Block Grant Fund allocations are also included for the FMAP match. The bill also includes General Fund appropriations to the Department of Administrative and Financial Services of $170,000 for the estimated cost to reimburse insurance carriers for 6 months of the State's defrayal cost of this new mandate. The mandate will go into effect on all health insurance plans on the marketplace beginning January 1, 2027 and is estimated to cost $340,000 annually thereafter. The State Employee Health Plan's first impacted plan year will be fiscal year 2027-28 and is estimated to cost $38,209 annually thereafter. The costs are split across the General Fund ($17,576), Highway Fund ($6,113) and all other funds ($14,519).